Overview

Study to Evaluate Improvements of the Quality of Sleep With NOVANUIT® Triple Action in Healthy Volunteers With Sleep Disorders

Status:
Completed

Trial end date:
2017-07-05

Target enrollment:

Participant gender:

Summary

Primary Objective: To estimate the range of improvement of NOVANUIT® triple action on sleep quality global score. Secondary Objectives: - To estimate the range of improvement of NOVANUIT® triple action on following parameters: time for getting asleep, sleep time, number of nocturnal awakening, number of nightmares, sleep quality (score from 0 to 10), and mean tiredness during the day (score from 0 to 10). - To estimate persistency of NOVANUIT® triple action effects after end of study product consumption. - To assess dependency to NOVANUIT® triple action after study product cessation. - To assess tolerance of NOVANUIT® triple action during the study.

Phase:

Phase 1

Details

Lead Sponsor:

Sanofi

Treatments:

Melatonin